News

e-Therapeutics to raise £40m
Enlarge image

BusinessUK

e-Therapeutics to raise £40m

12.02.2013 - AIM-listed cancer drug discovery specialist e-Therapeutics plc is set to
raise £40m to push its drug development.

The Oxford-based drug discovery and development company said it will issue new ordinary shares to institutional investors. The shares will be priced at 32p, a premium of 4%, to the closing mid-market price on share value of 8th February. The move was backed  by the company’s shareholders in advance of its general meeting.

With the proposed issue, e-Therapeutics wants to fill its pockets – pro-forma net cash and liquid resources will total approximately £48m after the capital increase. The company announced this will be enough money to support all of the company’s current R&D activities until 2017 by which the company expects to licence its lead compound, ETS2101.

Up to then £25m will be required to push the synthetic cannabinoid dexanabinol (ETS2101) from the current Phase I dose-escalation studies to proof-of concept in glioma and four to six additional solid cancer indications. Other investments will be made into new drug discovery efforts using the company’s network pharmacology platform. The funds to be raised through the new issue will include a substantial fund by existing investor Invesco Asset Management Limited, whose shareholding will increase from 45.92% to 49.90% after completion.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/e-therapeutics-to-raise-pound40m.html

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

PoliticsIrelandEU

06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.39 CHF21.87%
  • THERAMETRICS0.07 CHF16.67%
  • SANTHERA97.50 CHF5.98%

FLOP

  • 4SC0.78 EUR-8.24%
  • ADDEX3.36 CHF-5.62%
  • BIOFRONTERA1.95 EUR-2.50%

TOP

  • CYTOS0.39 CHF77.3%
  • ADDEX3.36 CHF44.2%
  • BB BIOTECH253.50 EUR28.1%

FLOP

  • ACTELION99.25 CHF-16.3%
  • BIOFRONTERA1.95 EUR-15.2%
  • 4SC0.78 EUR-13.3%

TOP

  • SANTHERA97.50 CHF2355.9%
  • BB BIOTECH253.50 EUR110.1%
  • FORMYCON12.40 EUR60.0%

FLOP

  • CYTOS0.39 CHF-88.1%
  • 4SC0.78 EUR-51.6%
  • MOLOGEN5.79 EUR-50.1%

No liability assumed, Date: 26.01.2015